Dianthus Therapeutics, Inc. Common Stock
$96.81
-$4.31 (-4.26%)
$96.47Day Range$104.55
Key Statistics
Market Cap
$5.66B
Shares Outstanding
55.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 12, 2023
Round Lot
100
Locale
US
Trading Data
Day Open
$101.12
Day High
$104.55
Day Low
$96.47
Volume
2.83M
VWAP
$97.44
Prev Close
$101.12
Transactions
--
Acc. Volume
--
About Dianthus Therapeutics, Inc. Common Stock
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
PHARMACEUTICAL PREPARATIONSSIC 283492 employees7 TIMES SQUARE, NEW YORK, NY, 10036929-999-4055IPO Sep 12, 2023US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001690585
- Composite FIGI
- BBG00FB2NPZ0
- Share Class FIGI
- BBG00FB2NQ15
- Ticker Root
- DNTH
- SIC Code
- 2834
About Dianthus Therapeutics, Inc. Common Stock (DNTH) Stock
Dianthus Therapeutics, Inc. Common Stock (DNTH) closed the 2026-09-18 session at $96.81, down 4.26% versus the previous close (-4.31). The stock opened at $101.12 and traded between $96.47 and $104.55 during that session. Session trading volume was 2.8M shares. The volume-weighted average price (VWAP) is $97.44.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Dianthus Therapeutics, Inc. Common Stock has a market capitalization of $5.66 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. DNTH is listed on the XNAS exchange. The company employs approximately 92 people. Dianthus Therapeutics, Inc. Common Stock is headquartered in NEW YORK, NY. The recorded listing date is 2023-09-12.
On this page you can find market DNTH stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.